Indivior Pharmaceuticals beats Q2 revenue on Sublocade growth, raises FY guidance
INDV•Outlook
- Indivior raised 2026 net revenue guidance to $1.295 bln-$1.365 bln from $1.215 bln-$1.285 bln
- Company now expects 2026 SUBLOCADE net revenue of $1.01 bln-$1.05 bln, up from $950 mln-$990 mln
- Indivior sees 2026 adjusted EBITDA of $700 mln-$740 mln, up from $620 mln-$660 mln
Overview
- U.S. opioid treatment maker's Q2 revenue rose 14%, beating analyst expectations
- Adjusted EPS for Q2 beat consensus
- Company repurchased $175 mln in shares during Q2
Result drivers and key details
- SUBLOCADE growth - Co said Q2 revenue growth was driven by a 21% year-over-year rise in SUBLOCADE net revenue, with U.S. SUBLOCADE revenue up 22% on 18% higher dispense unit volume and record new patient starts
- Lower operating expenses - Co reported a 25% year-over-year decrease in GAAP operating expenses and a 33% decrease in non-GAAP operating expenses in Q2
- Favorable pricing and adjustments - Co said net revenue benefited from more favorable price/mix and gross-to-net adjustments
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
